Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.
The HIV epidemic is a major threat to health in the developing and western worlds. A modality that targets and kills HIV-1-infected cells could have a major impact on the treatment of acute exposure and the elimination of persistent reservoirs of infected cells. The aim of this proof-of-principle st...
Main Authors: | Ekaterina Dadachova, Mahesh C Patel, Sima Toussi, Christos Apostolidis, Alfred Morgenstern, Martin W Brechbiel, Miroslaw K Gorny, Susan Zolla-Pazner, Arturo Casadevall, Harris Goldstein |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2006-11-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC1630718?pdf=render |
Similar Items
-
Combination of anti-retroviral drugs and radioimmunotherapy specifically kills infected cells from HIV infected individuals
by: Dina Tsukrov, et al.
Published: (2016-09-01) -
Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology.
by: Xing Guo Wang, et al.
Published: (2007-10-01) -
Immunoprophylaxis against mother-to-child transmission of HIV-1.
by: Miroslaw K Gorny, et al.
Published: (2006-07-01) -
Correction: Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication
by: Ekaterina Dadachova, et al.
Published: (2012-01-01) -
Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication.
by: Ekaterina Dadachova, et al.
Published: (2012-01-01)